Radius Health Inc. (RDUS) Stock Price Down 3.9%
Radius Health Inc. (NASDAQ:RDUS) shares fell 3.9% during mid-day trading on Wednesday . The company traded as low as $40.31 and last traded at $40.75, with a volume of 246,197 shares trading hands. The stock had previously closed at $42.41.
A number of research firms recently issued reports on RDUS. Zacks Investment Research upgraded Radius Health from a “sell” rating to a “hold” rating in a report on Monday, May 2nd. HC Wainwright began coverage on Radius Health in a report on Monday, May 23rd. They issued a “buy” rating and a $55.00 target price for the company. Canaccord Genuity reiterated a “buy” rating on shares of Radius Health in a report on Tuesday, May 31st. Cowen and Company began coverage on Radius Health in a report on Friday, May 6th. They issued an “outperform” rating for the company. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $70.00 target price on shares of Radius Health in a report on Thursday, March 31st. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $70.07.
The stock’s market capitalization is $1.75 billion. The firm’s 50 day moving average is $37.41 and its 200-day moving average is $36.07.
Radius Health (NASDAQ:RDUS) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by $0.20. During the same period last year, the business posted ($0.47) earnings per share. The firm’s revenue was up .0% on a year-over-year basis. On average, analysts anticipate that Radius Health Inc. will post ($3.71) earnings per share for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP purchased a new stake in Radius Health during the fourth quarter worth approximately $1,362,000. Wells Fargo & Company MN increased its stake in shares of Radius Health by 7.5% in the fourth quarter. Wells Fargo & Company MN now owns 422,217 shares of the biopharmaceutical company’s stock valued at $25,984,000 after buying an additional 29,601 shares in the last quarter. Mutual of America Capital Management LLC increased its stake in shares of Radius Health by 18.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 36,483 shares of the biopharmaceutical company’s stock valued at $2,245,000 after buying an additional 5,683 shares in the last quarter. EAM Investors LLC bought a new stake in shares of Radius Health during the fourth quarter valued at about $2,816,000. Finally, New York State Common Retirement Fund increased its stake in shares of Radius Health by 36.0% in the fourth quarter. New York State Common Retirement Fund now owns 69,048 shares of the biopharmaceutical company’s stock valued at $4,249,000 after buying an additional 18,259 shares in the last quarter.
Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company’s lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.